Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors

NCT06493552 is registered in ClinicalTrials.gov with Vasgene Therapeutics, Inc as lead sponsor.

NCT NCT06493552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06493552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors
Lead sponsor
Vasgene Therapeutics, Inc
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 15, 2025
Completion date
August 31, 2034
Enrollment
700 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial carcinoma, muscle-invasive bladder carcinoma